Cargando…
Can Elevated Pretreatment Serum Carcinoembryonic Antigen Levels Serve as a Potential Biomarker Guiding Adjuvant Chemotherapy in Rectal Cancer Patients With ypTis-3N0 After Neoadjuvant Radiotherapy and Surgery?
Survival benefit of adjuvant chemotherapy (ACT) remained controversial in patients with stage II/III rectal cancer (RC) who received neoadjuvant therapy and surgery. This study aimed to investigate the guiding role of elevated pretreatment serum carcinoembryonic antigen (CEA) levels for receiving AC...
Autores principales: | Huang, Chi, Jiang, Mingkun, Li, Yan, Tang, Chaoyang, Ma, Xiang, Huan, Xiangkun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369410/ https://www.ncbi.nlm.nih.gov/pubmed/34414115 http://dx.doi.org/10.3389/fonc.2021.705460 |
Ejemplares similares
-
Tumor budding outperforms ypT and ypN classification in predicting outcome of rectal cancer after neoadjuvant chemoradiotherapy
por: Trotsyuk, Iryna, et al.
Publicado: (2019) -
Pretreatment Carcinoembryonic Antigen Level Serves as a Potential Biomarker to Guide Adjuvant Radiotherapy in pT4N+ Colon Cancer Patients
por: Luo, Dakui, et al.
Publicado: (2023) -
Impact of adjuvant chemotherapy on patients with ypT0–2 ypN0 rectal cancer after neoadjuvant chemoradiation: a cohort study from a tertiary referral hospital
por: Galata, Christian, et al.
Publicado: (2018) -
Is adjuvant chemotherapy necessary for patients with ypT0–2N0 rectal cancer treated with neoadjuvant chemoradiotherapy and curative surgery?
por: Lu, Zhao, et al.
Publicado: (2018) -
Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0
por: You, Kai-yun, et al.
Publicado: (2014)